alexa
Reach Us +1-217-403-9671
The What Million Dollar Question: Patent Litigation And Strategy Under The Biologics Price Competition And Innovation Act | 8154
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

The what million dollar question: Patent litigation and strategy under the Biologics Price Competition and Innovation Act

International Conference and Exhibition on Biowaivers & Biosimilars

Bryan J. Vogel

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.002

Abstract
Umbilical cord and placenta, once considered medical waste are emerged to be a valuable source of stem cells. The cord blood stem cells show the potential to treat the fatal disease such as leukemia, cardiac attacks and debilitating disease including Alzeimer?s and Parkinson?s. Cord blood stem cells are also widely used in therapies such as blood disorders, bone and tissue engineering, dermatology etc. Isolated NPCs are able to proliferate in response to basic fibroblast growth factor and when the culture conditions are altered means addition of BDNF and NT-3, they differentiate into several phenotypes of neurons. Fabricated PCL with 10% sucrose and 10% PEG 4000 scaffold shown good proliferation rate upto 14 days while PCL with 5% sucrose shown to promote good cells attachement and survival rate more than 21 days this may be due to pore size & pore number. Intravenously transplanted NPCs can enter the mice brain with Parkinson disease, survive, migrate and improve functional recovery. Transplantation of human NPCs can be used to restore neurological deficits in experimental Parkinson disease
Biography
Bryan J. Vogel is a partner in the New York office of the law firm of Robins, Kaplan, Miller, & Ciresi L.L.P. He is an Intellectual Property litigator with a practice emphasis in Life Sciences and Hatch-Waxman and biosimilars ligation and strategic counseling. He publishes frequently on general Intellectual Property topics, as well as matters specific to the Life Sciences community. He received his J.D. from George Washington University. In addition, he earned a B.S. in Chemical Engineering, with honors from Michigan State University, where he was also a member of Phi Beta Kappa and Tau Beta Pi (invited)
Top